Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 323 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Consolidation Clear all
Recruiting Phase 3 Interventional

D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

NCT07624513
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Isatuximab, Iberdomide, Bortezomib (B), Dexamethasone, Melphalan, Linvoseltamab, On Body Delivery System (OBDS)
Drug · Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 17, 2026, 11:50 PM EDT
Active, not recruiting Phase 1 Interventional

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

NCT05412290
View directory record Official record
Conditions
B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Follicular Lymphoma Grade 3
Interventions
Mosunetuzumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 11:50 PM EDT
Completed No phase listed Observational

Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients

NCT03488862
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 17, 2026, 11:50 PM EDT
Recruiting Phase 2 Interventional

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

NCT07415005
View directory record Official record
Conditions
Advanced Non-Small Cell Lung Cancer
Interventions
Lorlatinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 17, 2026, 11:50 PM EDT
Terminated Phase 3 Interventional Results available

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

NCT01662102
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Zevalin, Rituximab
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Sun City, Arizona • Athens, Georgia • Niles, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 17, 2026, 11:50 PM EDT
Terminated Phase 2 Interventional Results available

Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia

NCT01600053
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Lenalidomide
Drug
Lead sponsor
Thomas Kipps
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Oct 17, 2026, 11:50 PM EDT
Completed No phase listed Observational

Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation

NCT02170181
View directory record Official record
Conditions
Cancer Patients Receiving Stereotactic Body RTX
Interventions
SBRT
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 17, 2026, 11:50 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse

NCT00462865
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine and Capecitabine and Avastin
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Albuquerque, New Mexico • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 17, 2026, 11:50 PM EDT
Terminated Phase 3 Interventional Results available

Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

NCT05020665
View directory record Official record
Conditions
Nucleophosmin 1-mutated Acute Myeloid Leukemia
Interventions
Entospletinib, Placebo, Cytarabine, Anthracycline
Drug
Lead sponsor
Kronos Bio
Industry
Eligibility
18 Years to 74 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 17, 2026, 11:50 PM EDT
Recruiting Phase 2 Interventional

Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma

NCT05366829
View directory record Official record
Conditions
Carcinoma, Hepatocellular, Liver Cell Carcinoma
Interventions
Tislelizumab
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 17, 2026, 11:50 PM EDT
Completed Phase 2 Interventional Results available

UARK 2003-33, Total Therapy III

NCT00081939
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Thalidomide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 17, 2026, 11:50 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma

NCT00244946
View directory record Official record
Conditions
Lymphoma
Interventions
therapeutic autologous lymphocytes, carmustine, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation (PBSCT)
Biological · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
15 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2015 · Synced Oct 17, 2026, 11:50 PM EDT
Completed Not applicable Interventional

Optimizing Exposure Therapy With Mental Rehearsal

NCT03934385
View directory record Official record
Conditions
Anxiety Disorders, Arachnophobia
Interventions
Mental Rehearsal, Exposure
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 17, 2026, 11:50 PM EDT
Active, not recruiting Phase 1 Interventional

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

NCT02632708
View directory record Official record
Conditions
Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), AML Arising From Antecedent Hematologic Disorder (AHD), AML Arising After Exposure to Genotoxic Injury
Interventions
AG-120, AG-221, cytarabine, daunorubicin, idarubicin, mitoxantrone, etoposide
Drug
Lead sponsor
Institut de Recherches Internationales Servier
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 17, 2026, 11:50 PM EDT
Completed Phase 2 Interventional

DOXIL for Consolidation Therapy in Ovarian Cancer.

NCT00248248
View directory record Official record
Conditions
Ovarian Neoplasm
Interventions
liposomal doxorubicin
Drug
Lead sponsor
Southeastern Gynecologic Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 17, 2026, 11:50 PM EDT
Completed Phase 1 Interventional

A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)

NCT01390337
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
AC220, daunorubicin, cytarabine
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Jacksonville, Florida • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 17, 2026, 11:50 PM EDT
Completed Not applicable Interventional

Physical Activity to Improve Patient Reported Outcomes for Adults With Acute Leukemia

NCT04552912
View directory record Official record
Conditions
Physical Activity, Exercise, Acute Leukemia, Consolidation, Maintenance Therapy
Interventions
Build Stamina Program
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 23, 2022 · Synced Oct 17, 2026, 11:50 PM EDT
Completed Phase 3 Interventional Results available

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

NCT00085709
View directory record Official record
Conditions
Leukemia
Interventions
gemtuzumab ozogamicin, observation, Cytosine arabinoside, Daunomycin
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 60 Years
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
255
States / cities
Anchorage, Alaska • Fort Smith, Arkansas • Little Rock, Arkansas + 161 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Oct 17, 2026, 11:50 PM EDT
Recruiting Phase 2 Interventional

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

NCT03586609
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Cladribine, Cytarabine, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
50 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 17, 2026, 11:50 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma

NCT00059839
View directory record Official record
Conditions
Lymphoma
Interventions
doxorubicin hydrochloride, mercaptopurine, methotrexate, prednisone, vinblastine sulfate, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 20 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
136
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 117 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 17, 2026, 11:50 PM EDT
Completed Phase 2 Interventional Results available

Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant

NCT01706666
View directory record Official record
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
bortezomib, cyclophosphamide, lenalidomide, laboratory biomarker analysis, dexamethasone, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Scottsdale, Arizona • Baltimore, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Oct 17, 2026, 11:50 PM EDT
Completed Early Phase 1 Interventional

Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia

NCT01843634
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
ODSH
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 17, 2026, 11:50 PM EDT
Completed Phase 2 Interventional Results available

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

NCT03202628
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Pomalidomide
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 17, 2026, 11:50 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Durvalumab, Tremelimumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
34
States / cities
Tucson, Arizona • Santa Rosa, California • New Haven, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 17, 2026, 11:50 PM EDT